2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: L7

Antiphospholipid Syndrome without Anticoagulation: 0utcome of 50 Patients
Abstract Number: 5

Antiphospholipid-Associated Nephropathy Is a Risk for Developing Arterial Thromboses in Patients with Systemic Lupus Erythematosus
Abstract Number: 2108

Anxiety in Caregivers of Patients with Chronic Rheumatic Conditions
Abstract Number: 1102

Anxiety in Fibromyalgia Patients
Abstract Number: 2786

Aortitis: Outcomes from a Cohort of 196 Patients
Abstract Number: 984

Apolipoprotein B Is a Target of T and B Cell Responses in a Subgroup of Patients with Lyme Disease
Abstract Number: 1791

Applicability of the 2006 European League Against Rheumatism (EULAR) Criteria for the Classification of Henoch-Schönlein Purpura. an Analysis Based on 766 Patients with Cutaneous Vasculitis
Abstract Number: 1989

Application of an Experiential Learning Framework for Clinician Scholar Educator Training in a Rheumatology Fellowship
Abstract Number: 2714

Application of the 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis in Korean Patients with Raynaud Phenomenon
Abstract Number: 666

Approach to Discriminate Treatment Impact in Both Moderate and Severe SLE: The Atacicept Phase IIb Trial Design
Abstract Number: 2355

Apremilast, a Novel Phosphodiesterase 4 Inhibitor, and Methotrexate Independently Prevent Inflammation in Vivo and in Vitro
Abstract Number: 1561

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, and the Impact of Baseline Weight and BMI on ACR20 and HAQ-DI Response: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
Abstract Number: 955

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pharmacodynamic Results of a Phase 3, Randomized, Controlled Trial
Abstract Number: 1565

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Improvement of Pain, Fatigue, and Disability in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials
Abstract Number: 1590

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].